Autoimmunity, COVID-19, Post-COVID-19 Syndrome and COVID-19 Vaccination covers all aspects of what is perhaps the most dramatic health crisis in the history of modern medicine. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) raised major concerns about the association between the virus and various autoimmune manifestations. Over 15 distinct autoantibodies and above 10 different autoimmune diseases were found to develop in COVID-19 patients. Moreover, evidence about recovered COVID-19 patients demonstrates that persistent systemic symptoms, which are believed to have an autoimmune-related mechanism, do exist.
As it is of great importance to recognize those autoimmune manifestations of COVID-19 and post-COVID-19 syndrome to properly cope with their outcomes in the ongoing pandemic and the long-term post-pandemic period, this book fulfills a vital need in the medical community.
1. Autoimmunity, COVID-19, Post-COVID19 Syndrome and COVID-19 Vaccination - p. iii 2. Cover - p. iii 3. Title Page - p. iii 4. Copyright - p. iv 5. Table Of Contents - p. iv 6. List of contributors - p. xiii 7. About the editors - p. xix 8. Foreword - p. xxi 9. Preface - p. xxiii 10. Chapter 1 Setting a context for autoantibodies, autoimmunity, and autoimmune diseases associated with SARS-CoV2 - p. 1 11. Chapter 2 The mosaic of autoimmunity and autoinflammation and SARS-CoV-2 as an environmental factor - p. 17 12. Chapter 3 Innate immune responses in COVID-19 - p. 63 13. Chapter 4 The role of T cell immunity in COVID-19 - p. 129 14. Chapter 5 Laboratory characteristics of cytokine storm syndrome in COVID-19 infection - p. 141 15. Chapter 6 COVID-19 - p. 161 16. Chapter 7 Genetic predisposition to COVID-19 and post-COVID syndrome - p. 173 17. Chapter 8 Molecular mimicry and SARS-CoV-2 - p. 185 18. Chapter 9 In silico study of molecular mimicry between SARS-CoV-2 and neutrophil extracellular traps composition in granulocyte-rich supernatants of patients with systemic lupus erythematosus and lupus nephritis - p. 199 19. Chapter 10 COVID-19 and the hyperferritinemic syndromes - p. 275 20. Chapter 11 SARS-CoV-2 and microbiome - p. 279 21. Chapter 12 Molecular and immunological evidence for SARS-CoV-2 being the autoimmune virus - p. 339 22. Chapter 13 Autoantibodies neutralizing antiinflammatory mediators in the context of SARS-CoV-2 infection and COVID-19 - p. 351 23. Chapter 14 What is common to MDA5 and COVID-19? - p. 369 24. Chapter 15 Humoral immunity and thrombosis in COVID-19 - p. 375 25. Chapter 16 Peripheral nervous system manifestations associated with COVID-19 - p. 393 26. Chapter 17 Central nervous system impairments in COVID-19 - p. 401 27. Chapter 18 Neuropsychiatric side of the COVID-19 - p. 405 28. Chapter 19 Myocarditis following vaccination with Pfizer-BioNTech BNT162b2 against coronavirus infection (COVID-19) - p. 427 29. Chapter 20 Rheumatic manifestations and autoimmunity associated with COVID-19 - p. 437 30. Chapter 21 SARS-CoV-2 induction and COVID-19 manifestations related to autoimmune gastrointestinal diseases - p. 451 31. Chapter 22 Multisystem inflammatory syndrome in children - p. 471 32. Chapter 23 Anosmia in COVID-19 and post-COVID syndrome - p. 487 33. Chapter 24 The effect of COVID-19 on patients with preexisting autoimmune diseases - p. 495 34. Chapter 25 COVID-19 in patients with Systemic Lupus Erythematosus and the antiphospholipid syndrome - p. 529 35. Chapter 26 Psoriatic arthritis and psoriasis in the era of COVID-19 - p. 557 36. Chapter 27 Thyroid autoimmunity and COVID-19 - p. 567 37. Chapter 28 Variation of the COVID-19 characteristics between genders - p. 577 38. Chapter 29 SARS-CoV-2, fertility-related autoantibodies and reproductive injury - p. 595 39. Chapter 30 Maternal and fetal issues in COVID-19-mediated thromboinflammation - p. 603 40. Chapter 31 Animal models of COVID-19 and complications - p. 623 41. Chapter 32 Risk assessment for aerosol infection by SARS-CoV-2 and protection by respirators and surgical masks - p. 637 42. Chapter 33 Therapeutic options in COVID-19 - p. 647 43. Chapter 34 Intravenous immunoglobulin and convalescent plasma treatment in the COVID-19 patient - p. 673 44. Chapter 35 Interaction between vitamin D deficiency and COVID-19 - p. 685 45. Chapter 36 Side effects of the COVID-19 vaccines - p. 711 46. Chapter 37 The post-COVID syndrome - p. 747 47. Chapter 38 Disease course and pathogenesis of post-COVID-19 condition - p. 759 48. Chapter 39 Long-term assessment of autoantibodies in post-COVID syndrome - p. 771 49. Chapter 40 Post-COVID-19 syndrome and fibromyalgia - p. 777 50. Chapter 41 Treatment and prevention of the post-COVID syndrome - p. 783 51. Index - p. 791
Autoimmunity, COVID-19, Post-COVID-19 Syndrome and COVID-19 Vaccination covers all aspects of what is perhaps the most dramatic health crisis in the history of modern medicine. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) raised major concerns about the association between the virus and various autoimmune manifestations. Over 15 distinct autoantibodies and above 10 different autoimmune diseases were found to develop in COVID-19 patients. Moreover, evidence about recovered COVID-19 patients demonstrates that persistent systemic symptoms, which are believed to have an autoimmune-related mechanism, do exist.
As it is of great importance to recognize those autoimmune manifestations of COVID-19 and post-COVID-19 syndrome to properly cope with their outcomes in the ongoing pandemic and the long-term post-pandemic period, this book fulfills a vital need in the medical community.
1. Autoimmunity, COVID-19, Post-COVID19 Syndrome and COVID-19 Vaccination - p. iii 2. Cover - p. iii 3. Title Page - p. iii 4. Copyright - p. iv 5. Table Of Contents - p. iv 6. List of contributors - p. xiii 7. About the editors - p. xix 8. Foreword - p. xxi 9. Preface - p. xxiii 10. Chapter 1 Setting a context for autoantibodies, autoimmunity, and autoimmune diseases associated with SARS-CoV2 - p. 1 11. Chapter 2 The mosaic of autoimmunity and autoinflammation and SARS-CoV-2 as an environmental factor - p. 17 12. Chapter 3 Innate immune responses in COVID-19 - p. 63 13. Chapter 4 The role of T cell immunity in COVID-19 - p. 129 14. Chapter 5 Laboratory characteristics of cytokine storm syndrome in COVID-19 infection - p. 141 15. Chapter 6 COVID-19 - p. 161 16. Chapter 7 Genetic predisposition to COVID-19 and post-COVID syndrome - p. 173 17. Chapter 8 Molecular mimicry and SARS-CoV-2 - p. 185 18. Chapter 9 In silico study of molecular mimicry between SARS-CoV-2 and neutrophil extracellular traps composition in granulocyte-rich supernatants of patients with systemic lupus erythematosus and lupus nephritis - p. 199 19. Chapter 10 COVID-19 and the hyperferritinemic syndromes - p. 275 20. Chapter 11 SARS-CoV-2 and microbiome - p. 279 21. Chapter 12 Molecular and immunological evidence for SARS-CoV-2 being the autoimmune virus - p. 339 22. Chapter 13 Autoantibodies neutralizing antiinflammatory mediators in the context of SARS-CoV-2 infection and COVID-19 - p. 351 23. Chapter 14 What is common to MDA5 and COVID-19? - p. 369 24. Chapter 15 Humoral immunity and thrombosis in COVID-19 - p. 375 25. Chapter 16 Peripheral nervous system manifestations associated with COVID-19 - p. 393 26. Chapter 17 Central nervous system impairments in COVID-19 - p. 401 27. Chapter 18 Neuropsychiatric side of the COVID-19 - p. 405 28. Chapter 19 Myocarditis following vaccination with Pfizer-BioNTech BNT162b2 against coronavirus infection (COVID-19) - p. 427 29. Chapter 20 Rheumatic manifestations and autoimmunity associated with COVID-19 - p. 437 30. Chapter 21 SARS-CoV-2 induction and COVID-19 manifestations related to autoimmune gastrointestinal diseases - p. 451 31. Chapter 22 Multisystem inflammatory syndrome in children - p. 471 32. Chapter 23 Anosmia in COVID-19 and post-COVID syndrome - p. 487 33. Chapter 24 The effect of COVID-19 on patients with preexisting autoimmune diseases - p. 495 34. Chapter 25 COVID-19 in patients with Systemic Lupus Erythematosus and the antiphospholipid syndrome - p. 529 35. Chapter 26 Psoriatic arthritis and psoriasis in the era of COVID-19 - p. 557 36. Chapter 27 Thyroid autoimmunity and COVID-19 - p. 567 37. Chapter 28 Variation of the COVID-19 characteristics between genders - p. 577 38. Chapter 29 SARS-CoV-2, fertility-related autoantibodies and reproductive injury - p. 595 39. Chapter 30 Maternal and fetal issues in COVID-19-mediated thromboinflammation - p. 603 40. Chapter 31 Animal models of COVID-19 and complications - p. 623 41. Chapter 32 Risk assessment for aerosol infection by SARS-CoV-2 and protection by respirators and surgical masks - p. 637 42. Chapter 33 Therapeutic options in COVID-19 - p. 647 43. Chapter 34 Intravenous immunoglobulin and convalescent plasma treatment in the COVID-19 patient - p. 673 44. Chapter 35 Interaction between vitamin D deficiency and COVID-19 - p. 685 45. Chapter 36 Side effects of the COVID-19 vaccines - p. 711 46. Chapter 37 The post-COVID syndrome - p. 747 47. Chapter 38 Disease course and pathogenesis of post-COVID-19 condition - p. 759 48. Chapter 39 Long-term assessment of autoantibodies in post-COVID syndrome - p. 771 49. Chapter 40 Post-COVID-19 syndrome and fibromyalgia - p. 777 50. Chapter 41 Treatment and prevention of the post-COVID syndrome - p. 783 51. Index - p. 791
